The resurgence of covalent drugs
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Covalent inhibitors, also known as irreversible inhibitors, are a class of inhibitors that bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity, compared to that of non-covalent inhibitors, which achieve binding and inhibition of target proteins through non-covalent interactions such as hydrogen bond and van”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [30]
In the citing paper
“Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“Aided by recent advancements in structural biology and chemistry, covalent inhibitors have emerged as a potentially effective approach towards PPI inhibition [37, 38].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“The initial binding step (K1) and the subsequent chemical reaction step (kinact) are two important factors determining the selectivity of covalent inhibitors (Fig. 7) [37].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“For example, approximately 50% of patients with non-small-cell lung carcinoma (NSCLC) who initially responded to reversible EGFR inhibitors relapsed owing to the emergence of tumour cells that express EGFR with mutations at T790M and/or L858R in the ATP binding sit”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“An irreversible mechanism of action also helps to mitigate against competition by high intracellular concentrations of AT”
BackgroundLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Cited by
Items 201–300 of 1,001
Reversible lysine-targeted probes reveal residence time-based kinase selectivity
Yang, T., Cuesta, A., Wan, X., Craven, G. B., Hirakawa, B. P., Khamphavong, P. L., May, J. R., Kath, J. C., Lapek, J. D., Niessen, S., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01019-1 · Cited by 114
Avoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106
Selective Metal-Site-Guided Arylation of Proteins
Willwacher, J., Raj, R., Mohammed, S., & Davis, B. G. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b04043 · Cited by 108
New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design
Ray, S., & Murkin, A. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00293 · Cited by 108
Thiol redox biology of trypanosomatids and potential targets for chemotherapy
Leroux, A. E., & Krauth‐Siegel, R. L. (2015) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2015.11.003 · Cited by 105
Recent Progress and Prospects of Small Molecules for NLRP3 Inflammasome Inhibition
Li, N., Zhang, R., Tang, M., Zhao, M., Jiang, X., Cai, X., Ye, N., Su, K., Peng, J., Zhang, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01370 · Cited by 109
Rodina, A., Patel, P. D., Kang, Y., Patel, Y., Baaklini, I., Wong, M. J. H., Taldone, T., Yan, P., Yang, C., Maharaj, R., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.10.008 · Cited by 105
Brameld, K. A., Owens, T. D., Verner, E., Venetsanakos, E., Bradshaw, J. M., Phan, V. T., Tam, D., Leung, K., Shu, J., LaStant, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00360 · Cited by 96
Liganding Functional Tyrosine Sites on Proteins Using Sulfur–Triazole Exchange Chemistry
Brulet, J. W., Borne, A. L., Yuan, K., Libby, A. H., & Hsu, K.-L. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c00648 · Cited by 101
Inhibitors of c-Jun N-Terminal Kinases: An Update
Koch, P., Gehringer, M., & Laufer, S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501212r · Cited by 112
Recent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 122
“Although covalent binders can be toxic due to the undesired modification of off-target proteins or haptenization [8,12], compounds that rely on covalent mechanisms are among the major classes of small molecules, representing about 30% of all active substances on the market.”
BackgroundWilliamson, A. E., Ylioja, P. M., Robertson, M. N., Antonova‐Koch, Y., Avery, V. M., Baell, J. B., Batchu, H., Batra, S., Burrows, J. N., Bhattacharyya, S. S., et al. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00086 · Cited by 114
Macip, G., Garcia‐Segura, P., Mestres‐Truyol, J., Saldivar‐Espinoza, B., Ojeda, M. J., Gimeno, A., Cereto‐Massagué, A., García-Vallvé, S., & Pujadas, G. (2021) · Medicinal Research Reviews · doi:10.1002/med.21862 · Cited by 115
“For irreversible covalent inhibitors, if a sufficient period of time is allowed, inhibition is expected to be complete.(86) Thus, conventional IC50 measurements are of limited value for characterizing the potency of irreversible inhibitors because incubation for a different period of time would provide a different IC5…”
BackgroundStructure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2
Ward, R. A., Colclough, N., Challinor, M., Debreczeni, J. E., Eckersley, K., Fairley, G., Feron, L. J. L., Flemington, V., Graham, M. A., Greenwood, R. D. R., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00466 · Cited by 107
Alkyne-Tag SERS Screening and Identification of Small-Molecule-Binding Sites in Protein
Ando, J., Asanuma, M., Dodo, K., Yamakoshi, H., Kawata, S., Fujita, K., & Sodeoka, M. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b06003 · Cited by 102
Advanced Activity-Based Protein Profiling Application Strategies for Drug Development
Wang, S., Tian, Y., Wang, M., Wang, M., Sun, G., & Sun, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00353 · Cited by 119
“However, covalent drugs have raised various concerns in the field of drug development (Singh et al., 2011; Bauer, 2015; Pichler et al., 2016).”
BackgroundType II Kinase Inhibitors: An Opportunity in Cancer for Rational Design
Blanc, J., Geney, R., & Menet, C. J. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313050008 · Cited by 111
Berteotti, A., Vacondio, F., Lodola, A., Bassi, M., Silva, C., Mor, M., & Cavalli, A. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400489b · Cited by 100
Strategies for targeting undruggable targets
Zhang, G., Zhang, J., Gao, Y., Li, Y., & Li, Y. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1969359 · Cited by 99
“more specific, the targeted covalent inhibitors (TCIs)[1].”
BackgroundXu, H., Chen, J., Chen, P., Li, W., Shao, J., Hong, S., Wang, Y., Chen, L., Luo, W., & Liang, G. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.014 · Cited by 105
Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors
Niessen, S., Dix, M. M., Barbas, S., Potter, Z. E., Lu, S., Brodsky, O., Planken, S., Behenna, D. C., Almaden, C., Gajiwala, K. S., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.017 · Cited by 99
Covalent Small Molecules as Enabling Platforms for Drug Discovery
Dalton, S. E., & Campos, S. (2019) · ChemBioChem · doi:10.1002/cbic.201900674 · Cited by 104
A Review of Small Molecule Inhibitors and Functional Probes of Human Cathepsin L
Dana, D., & Pathak, S. K. (2020) · Molecules · doi:10.3390/molecules25030698 · Cited by 108
“There are, however, several examples of successful drugs being used in clinics that work by an irreversible inhibitory mechanism [91].”
BackgroundTunable Methacrylamides for Covalent Ligand Directed Release Chemistry
Reddi, R. N., Resnick, E., Rogel, A., Rao, B. V., Gabizon, R., Goldenberg, K., Gurwicz, N., Zaidman, D., Plotnikov, A. N., Barr, H. M., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10644 · Cited by 105
Privileged scaffolds in lead generation
Zhao, H., & Dietrich, J. D. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1041496 · Cited by 110
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
BackgroundPlanken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01894 · Cited by 97
Expanding the scope of electrophiles capable of targeting K-Ras oncogenes
McGregor, L. M., Jenkins, M. L., Kerwin, C., Burke, J. E., & Shokat, K. M. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00271 · Cited by 97
Gushwa, N. N., Kang, S., Chen, J., & Taunton, J. (2012) · Journal of the American Chemical Society · doi:10.1021/ja310659j · Cited by 97
Keeley, A. B., Ábrányi-Balogh, P., & Keserű, G. M. (2018) · MedChemComm · doi:10.1039/c8md00327k · Cited by 97
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality
Kostic, M., & Jones, L. H. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.02.006 · Cited by 91
“Covalent inhibitors have seen a resurgence of clinical and drug development relevance, driven primarily by the recent approvals of several covalent kinase inhibitors, such as afatinib, ibrutinib and osimertinib, for the treatment of cancer [10] [11].”
BackgroundTargeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge
Picarazzi, F., Vicenti, I., Saladini, F., Zazzi, M., & Mori, M. (2020) · Molecules · doi:10.3390/molecules25235695 · Cited by 100
“TCIs are specifically designed with a functional group that is able to react with a specific residue of the target prot in, forming a covalent complex that may lead to th loss of protein activity [87,88].”
BackgroundBeyond cysteine: recent developments in the area of targeted covalent inhibition
Mukherjee, H., & Grimster, N. P. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.011 · Cited by 95
Covalent targeting of acquired cysteines in cancer
Visscher, M., Arkin, M. R., & Dansen, T. B. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.11.004 · Cited by 95
“For example, two of the most widely prescribed cancer drugs — the proteasome inhibitor bortezomib and the CYP17 inhibitor abiraterone acetate — bind their target covalently (for more examples see [7]).”
Zheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 108
Vavricka, C. J., Liu, Y., Kiyota, H., Sriwilaijaroen, N., Qi, J., Tanaka, K., Wu, Y., Li, Q., Li, Y., Yan, J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2487 · Cited by 98
MAP Kinase-Interacting Kinases—Emerging Targets against Cancer
Diab, S., Kumarasiri, M., Yu, M., Teo, T., Proud, C. G., Milne, R. W., & Wang, S. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.01.011 · Cited by 97
An update on the discovery and development of reversible covalent inhibitors
Faridoon, F., Ng, R. A., Zhang, G., & Li, J. J. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03065-3 · Cited by 106
“within a target protein family if a poorly conserved cysteine is specifically targeted with a covalent warhead from a drug [2, 4].”
BackgroundVersatile Bioconjugation Chemistries of ortho-Boronyl Aryl Ketones and Aldehydes
Cambray, S., & Gao, J. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00154 · Cited by 99
Huang, Q., Zhong, Y., Dong, H., Zheng, Q., Shi, S., Zhu, K., Qu, X., Hu, W., Zhang, X., & Wang, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111922 · Cited by 91
The Semiempirical Quantum Mechanical Scoring Function for In Silico Drug Design
Lepšík, M., Řezáč, J., Kolář, M. H., Pecina, A., Hobza, P., & Fanfrlík, J. (2013) · ChemPlusChem · doi:10.1002/cplu.201300199 · Cited by 91
Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases
Schopfer, F. J., Vitturi, D. A., Jorkasky, D. K., & Freeman, B. Α. (2018) · Nitric Oxide · doi:10.1016/j.niox.2018.06.006 · Cited by 99
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.011 · Cited by 94
Identification of a potent and selective covalent Pin1 inhibitor
Pinch, B. J., Doctor, Z. M., Nabet, B., Browne, C. M., Seo, H., Mohardt, M. L., Kozono, S., Lian, X., Manz, T. D., Chun, Y., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0550-9 · Cited by 92
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Roskoski, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105422 · Cited by 87
Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα
Nacht, M., Qiao, L., Sheets, M. P., St. Martin, T., Labenski, M., Mazdiyasni, H., Karp, R., Zhu, Z., Chaturvedi, P., Bhavsar, D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3008745 · Cited by 88
Self-citationModeling covalent-modifier drugs.
Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90
Liu, Y., Xie, Z., Zhao, D., Zhu, J., Mao, F., Tang, S., Xu, H., Luo, C., Geng, M., Huang, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01245 · Cited by 90
Dounay, A. B., Anderson, M., Bechle, B. M., Campbell, B. M., Claffey, M. M., Evdokimov, A., Evrard, E., Fonseca, K. R., Gan, X., Ghosh, S., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200204m · Cited by 88
Quantum Chemical-Based Protocol for the Rational Design of Covalent Inhibitors
Schirmeister, T., Kesselring, J., Jung, S., Schneider, T. H., Weickert, A., Becker, J., Lee, W., Bamberger, D., Wich, P. R., Distler, U., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b03052 · Cited by 97
Growing PAINS in Academic Drug Discovery
Whitty, A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.44 · Cited by 88
Self-citationLou, Y. C., Owens, T. D., Kuglstatter, A., Kondru, R. K., & GOLDSTEIN, D. M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300035p · Cited by 91
Electrophilic Warhead-Based Design of Compounds Preventing NLRP3 Inflammasome-Dependent Pyroptosis
Cocco, M., Garella, D., Di Stilo, A., Borretto, E., Stevanato, L., Giorgis, M., Marini, E., Fantozzi, R., Miglio, G., & Bertinaria, M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501072b · Cited by 85
Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS
Li, N., Kuo, C. J., Paniagua, G., van den Elst, H., Verdoes, M., Willems, L. I., van der Linden, W. A., Ruben, M., van Genderen, E., Gubbens, J., et al. (2013) · Nature Protocols · doi:10.1038/nprot.2013.065 · Cited by 98
Structural approaches to obtain kinase selectivity
Norman, R. A., Toader, D., & Ferguson, A. D. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.005 · Cited by 86
Krenske, E. H., Petter, R. C., Zhu, Z., & Houk, K. N. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo200761w · Cited by 86
Self-citationCovalent tethering of fragments for covalent probe discovery
Kathman, S. G., & Statsyuk, A. V. (2016) · MedChemComm · doi:10.1039/c5md00518c · Cited by 90
Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors
Huhn, A. J., Guerra, R. M., Harvey, E. P., Bird, G. H., & Walensky, L. D. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.07.022 · Cited by 78
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy
Pang, X., Liu, X., Liu, Y., Liu, W., Li, Y.-R., Yu, G.-X., Tian, X., Zhang, Y., Song, J., Jin, C., et al. (2021) · Molecules · doi:10.3390/molecules26144250 · Cited by 85
“Recently, the discovery of irreversible covalent inhibitors targeting kinases has attracted great interest [87,88], which shows unique advantages, for example, irreversible covalent inhibitors could prolong the target retention time and obtain long-lasting inhibition without continuous administration, as well as reduc…”
BackgroundQuantitative Chemoproteomic Profiling with Data-Independent Acquisition-Based Mass Spectrometry
Yang, F., Jia, G., Guo, J., Liu, Y., & Wang, C. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11053 · Cited by 84
Rajasekaran, D., Zierow, S., Syed, M. A., Bucala, R., Bhandari, V., & Lolis, E. (2014) · The FASEB Journal · doi:10.1096/fj.14-256636 · Cited by 89
Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors
Avelar, L. A. A., Reyes, C. D. C., de Albuquerque, S., Fernandes, W. B., Gonçalez, C., Kenny, P. W., Leitão, A., McKerrow, J. H., Montanari, C. A., Orozco, E. V. M., et al. (2015) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003916 · Cited by 87
Zhu, Y., Li, L., Zhang, G., Wan, H., Yang, C., Diao, X., Chen, X., Zhang, L., & Zhong, D. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.08.009 · Cited by 84
McAulay, K., Hoyt, E. A., Thomas, M. C., Schimpl, M., Bodnarchuk, M. S., Lewis, H. J., Barratt, D. G., Bhavsar, D., Robinson, D. M., Deery, M. J., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b13391 · Cited by 91
“We attributed the instability of the cyclized systems ( 5a − c ) to intermolecular [4 + 2] cycloaddition of the ene-imine system, thus removal of the alkene group in favor of acetylene was investigated.”
MethodFu, L., Li, Z., Liu, K., Tian, C., He, J.-X., He, J., He, F., Xu, P., & Yang, J. H. (2020) · Nature Protocols · doi:10.1038/s41596-020-0352-2 · Cited by 95
Stereochemical diversity as a source of discovery in chemical biology
Scott, K. A., Ropek, N., Melillo, B. N., Schreiber, S. L., Cravatt, B. F., & Vinogradova, E. V. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100028 · Cited by 87
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 115
“216,217 The most typical example of covalent inhibitors is the design of EGFR inhibitors.”
BackgroundMolecular Dynamics Simulations in Drug Design
Kerrigan, J. E. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-342-8_7 · Cited by 89
McAllister, L. A., Butler, C. R., Mente, S., O’Neil, S. V., Fonseca, K. R., Piro, J. R., Cianfrogna, J. A., Foley, T. L., Gilbert, A. M., Harris, A. R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00070 · Cited by 91
Nam, D., Steck, V., Potenzino, R. J., & Fasan, R. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09504 · Cited by 83
Machine learning activation energies of chemical reactions
Lewis‐Atwell, T., Townsend, P. A., & Grayson, M. N. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1593 · Cited by 94
Yang, C., Wang, W., Liang, J., Li, G., Vellaisamy, K., Wong, C., Ma, D., & Leung, C. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00133 · Cited by 83
Chemical strategies to overcome resistance against targeted anticancer therapeutics
Pisa, R., & Kapoor, T. M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0596-8 · Cited by 86
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Fischer, P. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 82
Privileged Electrophile Sensors: A Resource for Covalent Drug Development
Long, M. J. C., & Aye, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.023 · Cited by 81
β-Glucosidase 2 (GBA2) Activity and Imino Sugar Pharmacology
Ridley, C. M., Thur, K. E., Shanahan, J. L., Thillaiappan, N. B., Shen, A., Uhl, K., Walden, C. M., Rahim, A. A., Waddington, S. N., Platt, F. M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463562 · Cited by 87
Proximity-enabled bioreactivity to generate covalent peptide inhibitors of p53–Mdm4
Hoppmann, C., & Wang, L. (2016) · Chemical Communications · doi:10.1039/c6cc01226d · Cited by 79
An improved model for fragment-based lead generation at AstraZeneca
Fuller, N. O., Spadola, L., Cowen, S. D., Patel, J. S., Schönherr, H., Cao, Q., McKenzie, A. R., Edfeldt, F., Rabow, A., & Goodnow, R. A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.023 · Cited by 81
Cardoso, R., Love, R., Nilsson, C. L., Bergqvist, S., Nowlin, D., Yan, J., Liu, K. K. ‐., Zhu, J., Chen, P., Deng, Y., et al. (2012) · Protein Science · doi:10.1002/pro.2172 · Cited by 79
“Recently, there is a renewed interest to target cysteine-containing proteins with irreversible inhibitors.(23) Considering the compact nature of the HIF-1a internal cavity and studies that indicate weak reactivity of thiol-based probes to cysteine residues buried in HIF-1a (unpublished results), we chose a”
BackgroundDeuterated Clopidogrel Analogues as a New Generation of Antiplatelet Agents
Zhu, Y., Zhou, J., & Jiao, B. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300460t · Cited by 78
Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt
Uhlenbrock, N., Smith, S. P., Weisner, J., Landel, I., Lindemann, M., Le, T. A., Hardick, J., Gontla, R., Scheinpflug, R., Czodrowski, P., et al. (2019) · Chemical Science · doi:10.1039/c8sc05212c · Cited by 88
CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors
Du, H., Gao, J., Weng, G., Ding, J., Chai, X., Pang, J., Kang, Y., Li, D., Cao, D., & Hou, T. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa876 · Cited by 80
“by rational structure design that combines the strengths of covalent and non-covalent modes of drug action (5,6).”
BackgroundRedox-dependent regulation of epidermal growth factor receptor signaling
Heppner, D. E., & van der Vliet, A. (2015) · Redox Biology · doi:10.1016/j.redox.2015.12.002 · Cited by 88
Aljoundi, A., Bjij, I., El-Rashedy, A. A. E., & Soliman, M. E. S. (2020) · The Protein Journal · doi:10.1007/s10930-020-09884-2 · Cited by 84
Natural Molecules Targeting Thioredoxin System and Their Therapeutic Potential
Zhang, J., Duan, D., Osama, A., & Fang, J. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8213 · Cited by 84
Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
Carmi, C., Mor, M., Petronini, P. G., & Alfieri, R. R. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.031 · Cited by 92
Direct Modulation of Small GTPase Activity and Function
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504357 · Cited by 76
Rational Tuning of Fluorobenzene Probes for Cysteine‐Selective Protein Modification
Embaby, A. M., Schoffelen, S., Kofoed, C., Meldal, M., & Diness, F. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201712589 · Cited by 78
Chemoproteomic methods for covalent drug discovery
Chan, W. C., Sharifzadeh, S., Buhrlage, S. J., & Marto, J. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00231g · Cited by 83
Zapf, C. W., Gerstenberger, B. S., Xing, L., Limburg, D. C., Anderson, D. R., Caspers, N., Han, S., Aulabaugh, A., Kurumbail, R., Shakya, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301190s · Cited by 75
Activity‐Based Protein Profiling: Recent Advances in Probe Development and Applications
Yang, P., & Liu, K. (2015) · ChemBioChem · doi:10.1002/cbic.201402582 · Cited by 91
Azetidine and Piperidine Carbamates as Efficient, Covalent Inhibitors of Monoacylglycerol Lipase
Butler, C. R., Beck, E. M., Harris, A. R., Huang, Z., McAllister, L. A., Ende, C. W. A., Fennell, K. F., Foley, T. L., Fonseca, K. R., Hawrylik, S. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01531 · Cited by 76
Drugging K-RasG12C through covalent inhibitors: Mission possible?
Ni, D., Li, X., He, X., Zhang, H., Zhang, J., & Lu, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.007 · Cited by 73
Zambaldo, C., Daguer, J.-P., Saarbach, J., Barluenga, S., & Winssinger, N. (2016) · MedChemComm · doi:10.1039/c6md00242k · Cited by 75
On-Demand Targeting: Investigating Biology with Proximity-Directed Chemistry
Long, M. J. C., Poganik, J. R., & Aye, Y. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b12608 · Cited by 75
Solubility and Bioavailability Enhancement of Oridonin: A Review
Zhang, Y., Wang, S., Dai, M., Nai, J., Zhu, L., & Sheng, H. (2020) · Molecules · doi:10.3390/molecules25020332 · Cited by 84
“alent drugs can react directly with targets to form covalent bonds, resulting in corres i i l ical activity [45].”
BackgroundInfluentialChen, P., Sun, J., Zhu, C., Tang, G., Wang, W., Xu, M., Xiang, M., Zhang, C., Zhang, Z., Gao, L., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202203878 · Cited by 79
Hodge, C. D., Edwards, R. A., Markin, C. J., McDonald, D., Pulvino, M. J., Huen, M. S. Y., Zhao, J., Spyracopoulos, L., Hendzel, M. J., & Glover, J. N. M. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00222 · Cited by 78
Designing Irreversible Inhibitors—Worth the Effort?
González‐Bello, C. (2016) · ChemMedChem · doi:10.1002/cmdc.201500469 · Cited by 74
Early phase drug discovery: Cheminformatics and computational techniques in identifying lead series
Duffy, B. C., Zhu, L., Decornez, H. Y., & Kitchen, D. B. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.062 · Cited by 80
Metadata
- Authors
- Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A.
- Affiliations
- University of Washington (US)
- Boston University (US)
- Corresponding author
- Singh, Juswinder
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 307-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2010993054
- Cited by
- 1,873
- References
- 71
- Citations by year
- 2026: 136 · 2025: 150 · 2024: 148 · 2023: 137 · 2022: 145 · 2021: 162 · 2020: 152 · 2019: 98 · 2018: 132 · 2017: 125 · 2016: 141 · 2015: 96 · 2014: 81 · 2013: 85 · 2012: 66
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM094551)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- covalent inhibitors, drug safety, covalent drug design, targeted covalent inhibitors
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Structure-Activity Relationship, Drug Design, Drug Delivery Systems, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.